March 3, 2020 / 1:15 PM / a month ago

BRIEF-CNS Pharmaceuticals Announces Brain Cancer Patient From Berubicin Phase 1 Trial Remains Cancer Free

March 3 (Reuters) - CNS Pharmaceuticals Inc:

* CNS PHARMACEUTICALS ANNOUNCES BRAIN CANCER PATIENT FROM BERUBICIN PHASE 1 TRIAL REMAINS CANCER FREE

* CNS PHARMACEUTICALS- INITIAL TRIAL WAS CONDUCTED IN 2006 AND AS OF FEB 2020, PATIENT HAS REMAINED CANCER FREE FOR OVER 13 YEARS

* CNS PHARMACEUTICALS - BERUBICIN PHASE 2 CLINICAL TRIALS TO BEGIN SUBJECT TO FDA IND APPROVAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below